Dr. Lal PathLabs shares jumped 8% from the day’s low after reporting a strong financial performance for the fourth quarter of FY25. As of 3 PM, the shares were trading 5.55% higher at Rs 2,943.00.
The company’s consolidated net profit for Q4 FY25 surged by 81% year-on-year, reaching ₹155.5 crore, compared to ₹85.8 crore in the same period last year.
The company’s total income for Q4 FY25 stood at ₹628.4 crore, reflecting an 11.4% growth from ₹563.8 crore in Q4 FY24. Revenue from operations also rose to ₹602.6 crore, up from ₹545.4 crore in Q4 FY24.
On the expense side, Dr. Lal PathLabs recorded total costs of ₹475 crore in the quarter, a slight increase from ₹443.9 crore in Q4 FY24. The primary cost drivers included employee benefits at ₹115.4 crore, cost of materials at ₹117.8 crore, and fees to collection partners, which amounted to ₹77.6 crore.
Profit before tax showed a substantial increase, rising to ₹153.4 crore in Q4 FY25, compared to ₹119.9 crore in Q4 FY24. Additionally, tax expenses recorded a net credit of ₹2.1 crore, attributed to deferred tax adjustments.
For the full fiscal year FY25, Dr. Lal PathLabs reported total income of ₹2,554.8 crore, up from ₹2,295.8 crore in FY24. The company also achieved a net profit of ₹492.2 crore, marking a significant increase from ₹362.3 crore in FY24. Total expenses for the year amounted to ₹1,930.1 crore, with an improved EBITDA margin compared to the previous year.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
